MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported Q1 2026 financial results highlighting progress in its endocrine and metabolic disorder pipeline. Key updates include the acceptance of Phase 2 trial data of canvuparatide for oral presentation at ENDO 2026, readiness to initiate Phase 3 trial in Q3 2026, and expansion of its obesity program with new candidate nominations. …